The Research Goes On…

Today, Dr Beljanski’s legacy continues through the work and support of the Beljanski Foundation. His research has garnered the attention of several prominent institutions in America. Mirko Beljanski’s work was not only confirmed but deepened:

• Upcoming new research projects:

Excellent initial results on pancreatic and ovarian cancer cells!

The work of Mirko Beljanski, PhD, has recently attracted the attention of the Medical Center at the University of Kansas, which resulted in a new and fruitful collaboration. Studies investigating the anti-cancer properties of the extracts of Pao pereira and Rauwolfia vomitoria and their effect on pancreatic and ovarian cancer cells are now underway at this institution.

A recently published abstract confirms that the two plant extracts, Pao pereira and Rauwolfia vomitoria inhibit cancer cell growth, even in those cells resistant to drugs used in chemotherapy. The results also show that healthy cells were not negatively affected, thus demonstrating the safety of the plant extracts prepared by the Beljanski method.

The Kansas scientists further examined the benefit of combining the two extracts with chemotherapy drugs. The synergy of action first demonstrated by him decades earlier has been verified with both pancreatic and ovarian cancer cells. These two types of cancer are particularly hard to treat.

These very promising results provide a further confirmation of Mirko Beljanski’s work. The study was first presented at a recent conference held in Oregon, USA. (Anti-cancer activity of extracts from Rauwolfia vomitoria and Pao Peiera: Integrative Medicine and Health, May 2012).

To learn more about these findings download the abstract at: http://www.biomedcentral.com/content/pdf/1472-6882-12-S1-P38

• Columbia University, New York (2004-2009) :

Columbia University, New York City.

At Columbia University, Dr. Aaron Katz’s team conducted more research to confirm the efficacy of the plant extracts as identified by Mirko Beljanski, Rauwolfia vomitoria and Pao pereira (Geissospermum vellosii). Dr. Aaron Katz, MD and Debra Bemis, PhD have explored and confirmed that the Rauwolfia vomitoria and the Pao pereira contains ß-Carbolines with interesting anticancer properties.

Publications of their findings:

• “A Novel Combination of Plant Extracts with Promising Anti-Prostate Cancer Activity” by John Hall, PhD, Natacha Springer, Msc, and Debra Bemis, PhD
  Townsend Letter – December 2004
• “Anti-prostate cancer activity of B-carboline alkaloid enriched extract from Rauwolfia vomitoria” by D.L. Bemis, J.L. Capodice, P. Gorroochurn, A.E. Katz and R. Buttyan
  International Journal of Oncology 29: 1065-1073, 2006
• “B-Carboline Alkaloid-Enriched Extract from the Amazonian Rain Forest Tree Pao Pereira Suppresses Prostate Cancer Cells” by Debra L. Bemis, PhD, Jillian L. Capodice, LAc, MS, Manisha Desai, PhD, Aaron E. Katz, MD, Ralph Buttyan, PhD
  Journal of the Society for Integrative Oncology, Vol 7, No 2 (Spring), 2009

Furthermore, a clinical trial to test the synergistic effects of Rauwolfia vomitoria and Pao pereira (Pau pereira) on men with a negative biopsy and elevated PSA was recently executed at the Columbia University, Department of Holistic Urology, under the direction of Dr. Geovanni Espinosa.

• “Two Herbal Extracts for Protecting Prostate Cell DNA – IMCJ April 2010” by Melissa Burchill, RN, CDN
  IMCJ (Integrative Medicine: A clinician’s journal) – April-May 2010

• Cancer Treatment Centers of America, Chicago (2010)

The prestigious Cancer Treatment Centers of America (CTCA) have recently completed a clinical trial on the extraordinary Beljanski formula of RNA fragments, which was conducted among cancer patients undergoing different chemotherapies. Thanks to the RNA fragments prepared according to Dr Beljanski’s proprietary process, the cancer patients all recovered a stronger immune system and managed to go through the end of their chemotherapy treatment without getting thrombocytopenia – a frequent and dangerous side effect of the chemotherapy drugs.

Publication of the results:

“Dose escalation study of an antithrombacytopenic agent in patients with chemotherapy induced thrombocytopenia” by Robert D Levin, MaryAnn Daehler, James F Grutsch, John L Hall, Digant Gupta, Christopher G Lis. Levin
Online magazine Bio Med Central BMC Cancer 10:565 – 2010